| Names | |
|---|---|
| Preferred IUPAC name | N-(4-hydroxyphenyl)acetamide |
| Other names | Paracetamol DC90 p-Hydroxyacetanilide N-Acetyl-p-aminophenol APAP Acetaminophenum Acetaminofén |
| Pronunciation | /əˌsiː.təˈmɪn.ə.fən/ |
| Identifiers | |
| CAS Number | 103-90-2 |
| Beilstein Reference | 1409075 |
| ChEBI | CHEBI:46195 |
| ChEMBL | CHEMBL112 |
| ChemSpider | 1178 |
| DrugBank | DB00316 |
| ECHA InfoCard | 100.004.276 |
| EC Number | 103-90-2 |
| Gmelin Reference | 110262 |
| KEGG | C07151 |
| MeSH | D017382 |
| PubChem CID | 1983 |
| RTECS number | AK4375000 |
| UNII | 362O9ITL9D |
| UN number | 2811 |
| Properties | |
| Chemical formula | C8H9NO2 |
| Molar mass | 151.16 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | 0.7 g/cm3 |
| Solubility in water | Slightly soluble in water |
| log P | 0.46 |
| Vapor pressure | Vapor pressure: <0.1 hPa (20 °C) |
| Acidity (pKa) | 9.5 |
| Basicity (pKb) | 8.90 |
| Magnetic susceptibility (χ) | -7.6 x 10⁻⁶ cm³/mol |
| Dipole moment | 2.15 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 163.0 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -302.7 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -4426 kJ/mol |
| Pharmacology | |
| ATC code | N02BE01 |
| Hazards | |
| Main hazards | May cause damage to liver if swallowed in large quantities. |
| GHS labelling | Not classified as hazardous according to GHS |
| Pictograms | GHS07, GHS08 |
| Signal word | Warning |
| Hazard statements | May cause damage to organs through prolonged or repeated exposure. |
| Precautionary statements | Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center immediately. Store in a cool, dry place. Do not use with other products containing acetaminophen. Use only as directed. |
| NFPA 704 (fire diamond) | 1-1-0 |
| Autoignition temperature | 420°C |
| Lethal dose or concentration | LD50 (oral, rat): 338 mg/kg |
| LD50 (median dose) | 338 mg/kg (oral, rat) |
| NIOSH | MU4375000 |
| PEL (Permissible) | Not established |
| REL (Recommended) | 3 g/day |
| Related compounds | |
| Related compounds | 4-Aminophenol Phenacetin Acetanilide p-Phenylenediamine N-(4-hydroxyphenyl)acetamide |
| Property | Manufacturer Commentary & Technical Insights |
|---|---|
| Product Name | Acetaminophen DC90, also referred to in solid dosage manufacturing as Paracetamol Direct Compressible Grade 90. |
| IUPAC Name | N-(4-hydroxyphenyl)acetamide |
| Chemical Formula | C8H9NO2 |
| Synonyms / Trade Names | 4-Acetamidophenol, p-Hydroxyacetanilide, Paracetamol DC Grade, Acetaminophen DC90, Paracetamol Compacted |
| HS Code & Customs Classification | HS Code is typically 2924.29, under “Acyclic amides and their derivatives; salts thereof” in most jurisdictions. End-use application, form (direct compressible), and compaction additives affect the declared subheading or classification during customs clearance procedures. Manufacturers often clarify compaction/grade-specific modifiers to avoid misclassification. |
Acetaminophen DC90 is a direct compression grade used for pharmaceutical tablet production. Manufacturing this grade involves granulation or compaction of base acetaminophen powder. The process route—dry granulation, roller compaction, or wet granulation with excipient blending—determines critical performance traits. Manufacturers select raw materials based on compaction compatibility, residue profile, and trace impurity trends in base acetaminophen. Differences in particle size distribution, flow properties, and compaction response are specific to the chosen processing method.
Physical characteristics such as bulk density, particle size, and flowability are defined according to direct compressible (DC) grade specifications. These properties are tailored by adjusting granulation parameters and excipient system selection, typically in consultation with downstream formulators. Application-specific requirements, such as tablet hardness and dissolution behavior, drive the internal release criteria for DC grade acetaminophen.
Direct compressible grades like DC90 reduce blending and granulation steps in tablet production. Particulate flow, homogeneity, and moisture sensitivity affect storage environment and transfer system design. Packaging controls focus on moisture barrier integrity and prevention of fines segregation during transport, as these influence both safety and end-use dosage reproducibility.
For DC90, manufacturers choose base acetaminophen with a tight impurity profile, conforming to pharmacopeial monographs. The main process variables—binder concentration, compaction pressure, and blending protocol—are set to minimize batch variability. Key control points include in-process particle size analysis, loss-on-drying, and uniformity testing. Deviations in these can affect downstream tablet appearance, dissolution, and mechanical strength.
Impurity sources include process reagents, equipment contact points, and excipient cross-contamination. Purification strategies target the removal of p-aminophenol, degradation byproducts, and trace solvents. Ongoing in-process control tests during manufacturing address both chemical purity and particulate consistency.
Final product batch release is defined according to a combination of internal process capability data and customer-specific requirements for particle size, compressibility, and blending properties. Release protocols include both physical and chemical parameters, adjusted per region and end-use.
In direct compression grades such as DC90, acetaminophen typically presents as a free-flowing, white or almost white granular powder. The specific particle size, flow properties, and agglomeration level result from the direct compression modification, which distinguishes it from conventional crystalline forms. Granule integrity and compressibility are sensitive to moisture and the type of excipients used during granulation. High-quality DC90 retains low dusting on transfer and blends predictably with tablet fillers. Odorless in routine manufacture, any noticeable smell usually signals contamination or degradation.
Direct compression grades do not alter the fundamental melting point, which remains consistent with pure acetaminophen, although this property is rarely used for in-process control. Bulk density and tapped density are closely monitored for DC90 because they impact tableting performance and dosing consistency. Measured values are batch-dependent, and manufacturing runs are adjusted to tighten bulk density within ranges that suit typical tablet presses.
Standard production monitors moisture pickup and thermal stress. DC90 remains chemically stable under dry, moderate conditions but starts to degrade when exposed to elevated humidity or reactive excipients. Process design reduces risk of hydrolysis and oxidative impurities. Compatibility with tablet excipients is tested batchwise; formulations containing oxidizers or strong acids/alkalis are avoided. Reactivity with environmental gases such as NOx and O3 is minimal if storage is controlled.
Solubility remains primarily grade-independent; direct compression processing does not significantly increase aqueous solubility but changes dispersion properties. Manufacturing experience shows granulation aids can influence wettability in tablet blends, which affects disintegration, not baseline solubility. Solution preparation for QC or formulation trials uses purified water or ethanol, avoiding extremes of pH to minimize impurity formation. Any visible particulate formation during dissolution points to blend incompatibility or excipient residue.
| Property | Direct Compression Grade (DC90) | Comment |
|---|---|---|
| Appearance | White/Almost white granular powder | Visual control for contamination, agglomeration |
| Assay (HPLC/UV) | Specification depends on customer requirement | Assay range finalized per order and internal release |
| Loss on Drying | Grade-specific limits | Critical for tableting |
| Particle Size (d50, d90) | Grade-specific criteria | Linked to tableting and blend uniformity |
| Bulk/Tapped Density | Grade-specific range | Production target for direct compression |
Impurity content reflects raw material quality, reaction management, and finished product handling. Primary impurities in industrial production include 4-aminophenol and related compounds; each is routinely monitored by HPLC in final product and intermediates. Customers may request customized impurity thresholds depending on therapeutic, regulatory, or pharmacopoeial specification. Exceedance of threshold mandates product rejection or reprocessing. Any deviation triggers investigation into batch records and raw material lots.
Testing is performed according to validated internal methods or pharmacopoeial procedures (e.g., USP, Ph. Eur., JP), depending on target markets. Test method selection is specified by customer contract or national requirement. Batch is released only after full review of appearance, assay, impurity levels, particle size, and compressibility report. Any out-of-specification result leads to investigation and corrective action.
Raw material selection prioritizes consistent purity, provenance traceability, and regulatory compliance. Suppliers are routinely audited, and incoming p-aminophenol undergoes identity, impurity, and moisture screening before batch use. All excipients for DC grade conform to compendial requirements and are batch-certified.
Commercial synthesis involves acetylation of p-aminophenol with acetic anhydride or acetyl chloride. Route selection considers cost, impurity burden, and downstream purification load. Reaction conditions, such as temperature control and reagent dosing, are tightly managed to minimize over-acetylation and formation of colored or toxic byproducts. Any process revision must be validated to avoid adverse impact on downstream filtration or granulation.
Process steps include controlled acetylation, crystallization, and multi-stage filtration. Key control points center on intermediate color, pH, temperature, and pressing time for filter cake. Washing steps minimize carryover impurities, particularly 4-aminophenol and oxidative byproducts. For direct compression grades, an additional granulation and drying step ensures compressibility and flow. Process analytical technology is applied inline for critical attributes. Failure at any control step requires batch hold or investigation of process drift.
Release depends on passing all physical, chemical, and microbial checks. QC isolates any off-spec characteristics, tags suspect lots, and logs deviation for traceability. Quality assurance reviews full production, test, and cleaning records before batch moves to warehouse or is shipped. Customer-specific certification can include additional third-party laboratory reports or tailored documentation.
Under normal compounding, acetaminophen DC90 remains inert toward tablet excipients. In upstream synthesis, common reactions include nucleophilic acetylation. Significant reaction risk emerges if exposed to strong oxidizers or alkali during blending, which can degrade the active to colored and toxic species.
Synthesis step conditions remain confidential and are tuned per batch to maintain impurity levels below release thresholds. In the facility setting, temperature excursions are monitored, and catalyst loads are validated. Direct compression granulation avoids use of strong acids or bases, relying on mild, pharmaceutically acceptable solvents as warranted.
Main application is for pharmaceutical tablet compounding and over-the-counter oral dose preparations. Downstream manufacturability depends on preservation of direct compressibility, powder flow, and stability during secondary processing.
Storage areas are climate-controlled to maintain specified temperature and humidity ranges, avoiding fluctuations that promote hydrolysis or caking. For direct compression grades, exposure to ambient moisture in storage or transfer lines increases risk of flow loss and impairs tableting. Product is kept in sealed, light-opaque containers to minimize photochemical degradation, especially in warehouse environments with skylights or high UV.
Polyethylene drums and high-barrier multilayer bags are standard to prevent ingress of atmospheric moisture or reactive gasses. Compatibility testing with each packaging source confirms that extractables and leachables do not exceed regulatory requirements.
Shelf life depends on batch validation and customer-specific requalification intervals. Visual checks for yellowing, caking, or odor serve as primary indicators of degradation. Product showing any sign of physical change or elevated impurity upon retest is not released.
GHS status reflects the inherent toxicity of acetaminophen and the associated handling precautions for industrial bulk powder. The material is classified based on acute toxicity, irritation, and potential for specific organ effects if mishandled.
Powder handling protocols focus on limiting skin, eye, and inhalation exposure. Operators use dust control, protective equipment, and maintain low airborne particulate levels in production and packaging zones. Safety data and signage are updated per regulatory review or safety audit.
Toxicity profile covers acute, chronic, and reproductive endpoints, relying on available animal and epidemiology data. Occupational exposure limits are determined by regulatory authority or company risk assessment. Engineering controls include local exhaust, closed transfer systems, and real-time air monitoring where batch charging or sampling occurs. Accidental exposures are reported, tracked, and used to refine handling standards.
As a dedicated manufacturer of direct-compression grade Acetaminophen DC90, supply stability hinges on both bulk synthesis batch scheduling and multipart downstream finishing lines. Actual capacity depends not only on reactor throughput but also on DC90 blending and granulation line uptime since any process deviation influences the ready-to-ship output. Supply planning factors in preventive maintenance cycles, cleaning validation intervals, and campaign-based grade changeovers—variables that affect available production slots. Allocation becomes tighter during flu seasons, pandemics, or export constraint cycles, driving the need for advance forecast collaboration with volume buyers.
Confirmed lead time for DC90 is driven by blending slot assignment, relevant to both batch-size preference and customer-specific requirements (such as functional excipient blends). For global clients, procurement teams typically request minimum order quantities aligned with full pallet or container loads, balancing inventory costs against shipping economics. Certain regulatory-markets may demand longer qualification lead times at first approval; repeat orders revert to shorter cycles based on prior registration status.
Bulk packaging for DC90 varies by grade and end-market registration. Food-contact certified liners, FIBCs, and multi-layer bags in cartons are standard, with customization (child-resistant, tamper-evident, pharma-tailored) subject to prior agreement. Moisture-barrier integrity is verified per batch, due to the sensitivity of DC90 to moisture pick-up and flow alteration—particularly critical for direct-compression tableting applications.
Exports mostly follow FOB or CIF terms at main seaports, harmonizing with shipment regularity and client warehouse intake rhythm. Payment practices reference national compliance regimes; pharmaceutical clients often operate on L/C, while domestic or mature relationships may rely on net-term invoicing with supply-chain finance integration.
Benzene derivatives and p-nitrophenol are primary cost drivers, and volatility in their availability filters directly into input pricing. Steam, process water, and energy inputs weigh heavier during grid price hikes or supply interruptions—this shifts cost curves for upstream and downstream stages. Fluctuations stem from refinery margin swings, geopolitical events, environmental controls, and periodic regulatory audits affecting batch yields and lot rejections.
Shifts in coal or oil prices impact feedstock costs, especially in energy-intensive synthesis stages. Environmental compliance requirements, waste treatment surcharges, or production suspension due to regulatory investigation introduce unpredictability. Supply shortages can also filter in via excipient or intermediate availability, not only from raw ingredient volatility but also logistics jams, port bottlenecks, or cross-border inspections.
Grades diverge by compressibility index, impurity level, and granulation profile. Higher purity/low bioburden lots, particularly where EU GMP or US DMF listing is demanded, command premium pricing. Batch-to-batch traceability, custom testing for specific pharmacopeial references, and packaging certifications (halal, kosher, allergen-free) factor significantly into grade-based price tiers. Price differential exists for non-pharma, food, and veterinary specifications; granular-DC (Direct Compression) grades with enhanced flowability cost more to produce than regular powder or API-only supply.
World supply is heavily concentrated in a few Asia-Pacific economies. Market imbalance emerges during active ingredient shortages (e.g., force majeure at key API plants) or when downstream tableting capacity outpaces upstream synthesis output. Manufacturing disruptions ripple across regions since alternative DC90 sources with full regulatory registration remain limited.
US and EU buyers demand higher regulatory compliance, leading to segmented pricing. Japan’s quality and documentation protocols set barriers for generic entrants, sustaining higher import prices. India maintains a dual role—major raw supplier and regional formulator—but local capacity constraints can trigger spikes for export buyers. The China market remains the production backbone, but policy-driven shutdowns for environmental upgrades or energy rationing periodically restrict output.
In the near term, stability relies heavily on raw chemical markets and manufacturing cost pressures (energy, labor, regulatory overhead). If global demand continues at post-pandemic levels and primary production hubs maintain regulatory approvals, moderate upward pricing drift is likely by 2026, especially for grades with higher compliance and traceability profiles. Sustained energy inflation or major feedstock shortages may produce sharper escalations.
This forecast references internal shipment records, client RFQ patterns, published producer guidance, regional import/export records, and external market monitoring of key input commodities and regulatory alerts. Projections integrate known supplier lead time fluctuations, weighted client grade requirements, and past incidence of supply chain disruptions.
Recent years have seen temporary supply chain constraints driven by plant inspections and input shortages. Environmental policy shifts in primary producing regions have caused periodic shutdowns or curtailed operating rates, influencing both spot pricing and medium-term availability for DC90 grades. Capacity investments and process upgrades in select regions have marginally improved supply security for compliant grades.
Continuous tightening of documentation requirements (traceability, residual solvent analysis, bioburden monitoring) increases overhead and complicates grade release. Recent serialization and anti-counterfeiting initiatives in regulated markets require both process adaptation and packaging upgrades, pushing up per-unit production cost for validated DC90.
In response to global supply vulnerabilities, manufacturing teams reinforce in-process monitoring and expand multi-sourcing on critical intermediates. Advance allocation agreements, consignment stock arrangements, and upstream-downstream coordination stabilize output against logistical or market turbulence. Ongoing qualification for new process aids and alternate input grades supports consistent batch quality despite upstream variability.
Direct compression acetaminophen, produced as grade DC90, supports a range of solid dosage formulations. The pharmaceutical sector uses this grade primarily for tablet manufacturing, including pain and fever relief medications for both adults and pediatric formulations. Contract manufacturers focused on consumer tablet brands usually specify DC90 due to its behavior during high-speed compression. Veterinary pharmaceutical applications may also employ this grade, though material requirements can differ by jurisdiction.
| Application Sector | Preferred Grade | Rationale |
|---|---|---|
| Human Pharmaceuticals (Tablets) | DC90, higher-purity grades | Consistent particle size, compressibility, and controlled impurity profile support regulatory compliance. Brands oriented toward pediatric or chewable applications may request further reduction in certain impurities or modified physical characteristics. |
| Over-the-Counter (OTC) Brands | DC90 | The compressibility and flow properties of the DC90 grade match OTC tablet production needs. Granule morphology and downstream blending compatibility remain central to tablet line yield and uniformity. |
| Veterinary Drug Formulation | DC90 or animal-health-specific grades | Depending on country-specific requirements, purities may differ. Physical flow and compressibility align closely with human tablet manufacturing, but impurity ranges or excipient compatibility can shift by animal species and dose form. |
| Parameter | Application Sensitivity | Comments from Manufacturing Experience |
|---|---|---|
| Particle Size Distribution | Tablet compressibility, dissolution profile | Particle sizing is actively controlled in the final granulation step. Deviations outside customer spec can affect capping, lamination, and dissolution during end-product QC. Batch-to-batch consistency in sizing reduces troubleshooting at customer sites. |
| Residual Solvents | Regulatory and safety compliance | Government authorities may specify stricter solvent limits for pediatric or branded applications. The manufacturing team manages residue through validated drying and in-process monitoring. |
| Flowability | Automated tablet presses | Slumping or interrupted dosing trace directly to granule morphology and surface modification during the finishing process. Line engineers report variations result in hopper bridging or off-spec tablet hardness. |
| Impurity Levels (e.g., p-aminophenol, heavy metals) | Final use, regional guidelines | Synthesis route, raw materials, and batch purification affect these values. Demands for advanced impurity profiling typically come from multinational firms or high-profile OTC brands. |
Operations must specify whether the end use targets prescription, OTC, veterinary, or another segment. Tableting method (direct compression, wet granulation) may direct the choice between DC90 and special order variants.
Decision-makers reference pharmacopeial standards, import country guidelines, and any branded-product stipulations. Production teams engage with regulatory affairs to interpret monograph scope and allowable ranges. Documentation requests for audit-ready traceability often follow at this stage.
Customers communicating high-sensitivity applications prompt an internal review of available grades. Raw material sourcing controls, synthesis-step adjustments, and downstream purification are matched to target specification. Facility records cover batch quality trends to anticipate risk points for impurity drift.
Higher grades with custom impurity or granulation specifications may require longer production slots or dedicated line time. Large-volume requests leverage campaign manufacturing scheduling to control costs, while single-lot specialty orders may affect price and timeline. Account managers interface with supply planning to balance forecasted volume and manufacturing lead time.
Customers’ formulation teams conduct pilot runs to test actual performance with plant-scale equipment. Our QA/QC unit provides release data tracked by lot. Feedback from customer validation supports technical exchanges to refine the specification. Final grade selection follows a closed-loop interaction between production, QA, and customer technical teams.
A robust compliance structure forms the baseline for every batch of Acetaminophen DC90 produced at our site. Manufacturing operations align to certified quality management systems. For pharmaceutical excipient grades, emphasis rests on certified adherence to internationally recognized standards, with documented audit trails for both ISO series and GMP compliance as required for direct compression material supply. Facility audits by customers or regulatory agencies are frequently accommodated and typically include direct review of process controls, documentation oversight, and deviation handling.
Product release for DC grades, including Paracetamol DC90, depends on the final blend’s suitability for direct compression as demonstrated in batch-specific performance records. Certificate of Analysis is provided per lot, indicating tested parameters and compliance to grade-specific pharmacopeial monograph references, where applicable. Regulatory support may be supplied in the form of EDMF/DMF dossiers for registration purposes, aligned to customer submission needs. Certification scope always reflects actual in-plant process capability as verified by historical process validation, ongoing monitoring, and independent third-party audits.
Documented traceability is maintained from incoming raw materials through to final product release. Batch records, process logbooks, and in-line monitoring data are archived in accordance with regulatory and internal requirements. Process changes are strictly managed via formal change control procedures. Customers receive documentation upon request, including batch history, stability data if available, and detailed impurity profiles where required for approval processes. Reports on non-conformities, if any, are fully disclosed in the eventual release documentation.
Core capacity planning relies on a precise match between historical demand projections and real-time production scheduling. Facility investment focuses on building redundancy at key process stages—reactor, granulation, and final blending—to amplify output response when market signals shift. Ongoing communication with long-term partners informs batch campaign timing and capacity reservation, allowing customers to plan formulation rollouts or tender requirements with accurate supply chain risk assessment.
Production operations deliver consistent output due to vertically integrated process controls, extensive batch tracking, and raw material sourcing from qualified suppliers. Scheduling considers grade and lot size, with finished goods storage designed around compliance with handling requirements for humidity and segregation by lot or customer. Buffer stock programs are collaboratively defined for key partners to help ensure rapid fulfilment. Disruption mitigation receives ongoing focus—both through technical redundancy and staggered batch release plans.
Sample provision adheres to a documented protocol, prioritizing customers with defined technical evaluation plans. Pilot-scale and commercial-scale samples are available, and each sample batch is accompanied by full technical documentation and CoA. Sample quantities and grade may be tailored based on receiving site's registration needs or product development status. Customers are encouraged to provide feedback on sample performance for continuous process enhancement.
Business cooperation models adapt to evolving project timelines, regulatory milestones, and logistical variability. Structured supply agreements permit both fixed quantity commitments and forecast-based delivery adaptations. Joint inventory planning, delayed shipment release, and just-in-time manufacturing support respond to each customer’s operating model. Contractual frameworks supporting exclusive supply windows or responsive escalation of batch scale are available, with every modification tracked in compliance with documented quality assurance procedures.
Demand for acetaminophen DC90 has driven targeted development efforts in direct compression technology. In our plant, process chemists focus on producing compressible grades that suit high-speed tableting environments. This research targets consistent particle morphology and flow, which affects both powder feeding and die filling. Material scientists evaluate microcrystalline cellulose or excipient blends to stabilize compactibility over extended storage. Analytical research teams examine trace impurities originating from diverse synthetic routes, especially processes utilizing different acetylation agents, as batch-to-batch consistency in pharmaceutical formulations depends on trace impurity control close to detection limits. Customer feedback from formulation trials highlights the significance of minimizing lubricant sensitivity for DC grades, guiding formulation chemists to refine excipient interaction studies.
Some regions are shifting from wet granulation to direct compression in high-volume paracetamol production due to lower operational costs, reduced solvent handling, and higher throughput. End users increasingly request DC90 for chewable or orodispersible tablets, which challenges formulators to optimize mouthfeel and disintegration without masking primary actives. Certain multi-layer or combination tablets rely on DC90's compactibility profile to separate actives while avoiding capping or lamination. Laboratory efforts focus on matching DC90's pressure-hardness curve to the demands of new tablet shapes and high-cavity tooling commonly adopted for pediatric and geriatric markets.
Consistent stable flow in humidity-variable environments presents ongoing challenges. Production engineers monitor particle size distributions and water activity after milling and blending. In-process controls quantify bulk and tapped density at several stages, flagging anomalies before blending with excipients. Recent breakthroughs include continuous-process blending to minimize lot-to-lot variability in particle characteristics. Purification strategies to suppress p-aminophenol and related trace impurities require multi-stage crystallization and customized in-line filtration setups. Any process modification undergoes accelerated stability studies to confirm compatibility with regulatory release standards for DC90 grades.
Forecasted demand for acetaminophen DC90 is expected to outpace that for conventional powder grades, especially in regions transitioning to fully automated direct compression facilities. Market analysis teams note stronger interest in high-flow, compressible grades from contract manufacturers seeking to cut tableting cycle times. Regulatory focus on reduced solvent and energy consumption may amplify demand for DC process-compatible grades, as wet granulation faces scrutiny under new environmental standards. Price sensitivity remains highest in emerging markets, requiring continued process efficiency improvements for competitive positioning.
Direct compression demand advances technical development toward narrower particle size distributions and increased batch consistency. The adoption of automated, real-time in-line particle size and flow analyzers during API finishing is changing plant-floor controls. Continuous production lines reduce segregation risk and increase standards for in-process monitoring. Manufacturers that integrate rapid analytical feedback loops see faster troubleshooting and fewer off-batch lots.
Sustainability within DC90 production focuses on solvent minimization, water recycling, and energy management. Selecting raw materials sourced from ISO-certified suppliers supports traceability and reduces risk of cross-contamination from non-pharmaceutical processes. Process chemists pursue acetylation methods generating fewer organic by-products, working in conjunction with effluent treatment engineers to reduce the overall burden on wastewater systems. Sustainable packaging and logistics planning further reduces carbon intensity per delivered ton.
The technical support team provides pre-formulation guidance based on direct-user granulation practices and compression equipment type. Technical staff routinely review control parameters from sample batches, advising on API to excipient ratios and blending protocols. Routine visits to customer plants facilitate troubleshooting of compression issues such as sticking or capping, which may link to subtle moisture ingress or excipient interaction. Documentation provided covers analytical methods validation and sampling recommendations for DC90, addressing both regulatory and internal QA concerns.
Support staff tailor recommendations according to specific tablet geometry, hardness targets, and line speed. Guidance includes compatibility studies with new excipient matrices, impacts of temperature and humidity on flow and compaction, and modifications to pre-mixing times. Process specialists can interpret disintegration and dissolution data from pilot runs, recommending blend changes or resin substitutions to meet both pharmacopeial and customer-specific release profiles.
For any batch traced to application or compaction issues, quality engineers access retained samples and analytical records for traceability investigation. Real-time feedback systems flag any recurring complaints, prompting immediate technical engagement and, where necessary, process adjustment or batch retraction. Customer audits are encouraged and supported with full documentation on raw material traceability, in-process controls, and finished product test results according to DC90 grade requirements. Shipment, storage, and shelf-life inquiries receive documented response based on internal QA and storage simulation studies, recognizing that optimal shelf life depends on both local environmental factors and the excipient system employed.
Our facility specializes in the direct manufacture of Acetaminophen (Paracetamol DC90) for the pharmaceutical industry. We control every core step of the process, starting with raw material selection, through synthesis, granulation, drying, and tableting. The DC90 grade emerges from years of process refinement, allowing it to meet consistent flow, compressibility, and stability criteria. The production line integrates automated control systems to monitor particle size distribution and moisture levels in every batch.
Pharmaceutical firms draw on Acetaminophen DC90 for direct compression tablet manufacturing, where efficient throughput and reproducibility matter. This grade supports high-speed tableting lines—batch after batch—across pain relief and fever management product lines. The food supplement industry also runs DC90 as an active ingredient in chewable products, requiring both compressibility and acceptable taste. We see contract manufacturers adopting DC90 in their generic medicine programs, counting on predictable blending and quick batch turnaround for both domestic and export requirements.
Plant management drives every stage under a stringent quality framework. Dedicated Q.C. laboratories run validated analytical methods, using HPLC and loss-on-drying tests, before material approval. In-process inspections during granulation and compression confirm both the chemical assay and flow performance before packing. All production records are traceable to ensure each drum or carton matches regulatory and client audit needs. Consistency is not left to chance—it is measured, tracked, and enforced batch after batch throughout the year.
We pack Acetaminophen DC90 in fiber drums with double PE liners for moisture protection and easy handling on factory floors. Warehousing integrates temperature and humidity controls to preserve off-the-line batch quality during storage. We support supply programs for both local and international customers, scheduling regular shipments by pallet or container-load to synchronize with customer demand and prevent downtime in their production schedules.
Technical teams consult directly with client R&D and production managers during formulation changes or equipment upgrades. Experienced process chemists address tablet press troubleshooting and advise on compatibility with other excipients. When clients scale from pilot to commercial batch, our on-site technical staff provides documentation and direct feedback based on real factory experience—minimizing trial-and-error at the customer’s end.
Direct production means more than cost control. Pharmaceutical manufacturers cut process deviations by relying on a source who understands the demands of smooth-flowing, compressible material in continuous operations. Distributors working with tight lead times retain confidence, knowing quality and packaging never shift between batches. Procurement teams benefit from open batch traceability and documentation without intermediaries. By controlling every stage, from synthesis to shipment, we remove unpredictability and support sustained business operations for each link in the supply chain.
Direct compression has reshaped how pharmaceutical companies approach tablet manufacturing. Our Acetaminophen DC90 was developed in response to the rising demand for reliable, free-flowing materials ready for high-speed presses. Years of feedback from major generic producers and strict regulatory inspection shaped our approach to formulation and process control. The key is consistency—batch after batch—so production lines run smoothly and finished tablets pass final quality tests without delay.
Paracetamol DC90 comes ready for direct compression. Our formula relies on micronized paracetamol as the main component, combined with pharmaceutical excipients including pregelatinized starch and povidone. This blend achieves two goals: it improves the flow of powder and boosts compressibility, essential for robust tablets. We target around 90% paracetamol by weight in the total mix, hence the ‘DC90’ name. Each excipient is selected after pilot-scale trials confirm compatibility and performance in rotary tablet machines.
The powder blend’s compactability keeps tablets strong enough to withstand stripping, coating, and transportation. Excipients account for the rest of the composition, forming the matrix that gives tablets their physical strength. Each excipient batch goes through quality checks for particle size and moisture content. Carrying excess starch or moisture into tablet blends leads to poor tablet hardness or capping, even in minor deviations from strict tolerances. That’s why our production labs run regular in-process controls and maintain a full record of blend certifications for every shipment.
We set our paracetamol assay target between 90% and 92% in the final DC90 grade powder, tested by validated HPLC assay. Full traceability always backs each lot. Impurity profiles stay well within current pharmacopeial limits. Residual solvents, if used in binder prep, are tested to fall below defined thresholds. Moisture levels are held between 2.0% and 4.5% to balance flow and prevent sticking during tableting. Microbial counts remain under strict limits suitable for oral drug production.
Each batch report details the exact assay value and excipient ratio. We routinely cross-check our specifications against regional pharmacopoeias. Tablets compressed with our DC90 show optimal friability, disintegration, and dissolution when produced under standard commercial conditions. These parameters mean fewer reworks and lower downtime for our partners.
Production of DC90-grade paracetamol involves more than blending APIs and excipients. We invest in high-shear mixers, dust-controlled filling rooms, and line-side analytical labs. Routine cleaning, segregated air handling, and online metal detection protect every batch. We support scale-up simulation for new lines to avoid costly trial-and-error phases. Our technical team handles questions about formulation adjustments or troubleshooting during scale-up.
Our packaging for DC90 maintains material stability over extended storage. We ship in multi-layer PE-lined drums or custom FIBC sacks for bulk orders. Each unit carries a full batch COA and traceability records for complete supply chain security.
Over the years, we’ve supported process engineers facing tablet sticking, powder segregation, or sluggish flow in feeders. Our R&D works with partners to tweak powder blend ratios or customize binder levels for legacy press models or humid-plant environments. These hands-on adjustments keep projects on track and costs predictable. If stringent dissolution or friability requirements arise, we can recommend precise excipient modifications without exceeding approved pharmacopoeial limits.
Our daily focus remains on delivering DC90 paracetamol that meets current global standards, simplifies downstream operations, and helps our customers get safe, effective tablets to market without avoidable delays.
In every production cycle at our facility, we prioritize reliability, consistent product quality, and fully transparent logistics. Over years of manufacturing Acetaminophen (Paracetamol DC90), we have set standards anchored in operational efficiency and the needs of downstream pharmaceutical formulations. Our experience shows that clearly defined minimum order quantities (MOQ) and production lead times not only improve planning but also drive cost efficiency along the whole supply chain.
Our MOQ for Acetaminophen (Paracetamol DC90) stands at 500 kg per order. This figure did not arise arbitrarily; it reflects a balance between sustainable production economics and the needs of tablet manufacturers. Producing below this MOQ increases per-kilogram operational costs, which can compromise both workflow stability and pricing integrity. Sticking to this standard MOQ ensures each customer benefits from fresh material, complete batch traceability, and a consistent physical profile, particularly important for direct compression grades such as DC90. In our experience, customers rarely face challenges handling this minimum quantity, since most batch processes in tableting plants consume multiple drums quickly. For those scaling up or managing launch phases, this MOQ keeps ingredients within necessary shelf life, which is critical for both regulatory compliance and patient safety.
Our lead time for Acetaminophen (Paracetamol DC90) typically ranges from three to four weeks, calculated from the moment we receive your confirmed purchase order. As a manufacturer, we schedule orders directly into our main production lines. Each lot moves through raw material sourcing, granulation or blending, QC sampling, analysis, release, and analytical documentation. All steps are strictly documented and tracked in our ERP system. Our clients often bring new projects or rapid increases in demand, so every lead time communicated relies on available production slots and shipping schedules. By maintaining robust safety stock of base acetaminophen API and direct compression excipients, we shield our customers from most raw material volatility. Shipments leave our plant only after clearing internal quality review and obtaining all mandatory export documentation.
Shifting MOQs or compressing timelines can seem attractive to buyers, especially during flu season or in the face of sudden tenders. From the production floor, this puts strain on blending sequence, changeover protocols, and downstream logistics. Rushed jobs increase the risk of cross-contamination, batch inconsistency, and capacity conflicts around excipient blending or granulation. Operating within fixed minimums—both in quantity and time—keeps operations predictable and materials safe, without squeezing critical steps in cleaning validation, stability sampling, or batch record review. We have seen situations where last-minute rush orders introduce lapses in documentation or force partial shipments. This carries a burden all the way to the patient and our customers' quality systems.
For projects that require phased deliveries or coordinated global logistics, our team provides shipment schedules and batch allocation forecasts to streamline your production planning. For exceptional circumstances such as pandemic preparedness or urgent tenders, we mobilize extra production personnel and run extended shifts, but never at the expense of full QC protocol or production safety. Our sales and technical teams work hand-in-hand with purchasing, formulation, and QA groups to anticipate needs with advance planning.
Our commitment to a consistent MOQ and defined production lead ensures that our Acetaminophen (Paracetamol DC90) remains a stable, reliable component in your finished dosage forms, whether launching a new brand or running a mature, high-volume line. Manufacturing direct compression grades brings unique demands; predictable commercial terms keep production, logistics, and quality departments working at their best for both you and your end-users.
As a manufacturer with decades of experience supplying Acetaminophen DC90 directly to global pharmaceutical companies, we know regulatory expectations shape daily production decisions. Our Acetaminophen DC90 undergoes rigorous testing protocols, tracking every batch from raw material input through to finished, compressed granule. Each batch must fully meet current pharmacopoeial requirements—such as those set in the United States Pharmacopeia (USP), the European Pharmacopoeia (Ph. Eur.), and other major monographs, including physical parameters like particle size, bulk density, and compressibility.
Typically, direct compression grade acetaminophen must pass identity, assay, related substances, and loss on drying tests, with specifications defined in relevant pharmacopoeias. Tight in-house controls flag even minor deviations in impurity profiles, ensuring we supply a product ready for direct tablet manufacturing. Assay values for DC90 remain within pharmacopoeial tolerances for acetaminophen content, while rigorous checks prevent unacceptable levels of p-aminophenol or other impurities. Our documentation trail supports every statement of compliance—batch certificates are kept ready for audit or regulatory submission at all times.
Meeting global standards requires raw material tracing, process controls, and consistent environmental monitoring. We constantly review process parameters so every shipment meets client and regulator expectations for compliance and performance.
Direct compression acetaminophen offers good stability across most climate zones encountered during routine shipment. Granulated acetaminophen is not technically classified as temperature-sensitive cargo. It does not call for cold chain logistics or specialized, temperature-controlled freight under standard practice. During transport, our product retains declared quality and assay in ambient conditions—typical for most pharma excipients in tablet production.
Moisture remains one of the principal considerations for any hygroscopic pharmaceutical ingredient. To block humidity ingress, all our DC90 product leaves production in sealed, food-grade polyethylene liners housed in robust fiber drums or PE drums. Our packaging line operates under strict GMP conditions—every closure minimizes risk of external contamination. Shelf-life claims rely on this packaging standard and data from our stability testing across a range of storage temperatures and humidities.
Storing acetaminophen DC90 in a cool, dry place, away from direct sunlight, provides the best assurance for long-term stability during shipping and warehousing. Customs clearances and possible delays do not threaten the product’s integral properties if containers remain sealed and are not exposed to major temperature spikes. For shipping routes moving through tropical or desert climates, we recommend placing the drums in shaded or covered storage during transit stops, simply as a precaution against condensation risks.
Air and sea freight both serve as viable logistics solutions. Road freight can be arranged with temperature monitoring if clients specify this as a risk management step, but we have documented performance of our DC90 under various non-specialized freight scenarios. Supply chain experts at leading pharma firms trust our standard logistics—many have independently validated our product’s stability in real-world shipments.
Our technical and export teams regularly review updated requirements from global regulators. Each year brings new scrutiny of compliance records. We stay ready—updating process validation, raw material audits, and transfer protocols to reflect any change in pharmacopeial standards. Every batch reflects our commitment to product quality, regulatory compliance, and dependable supply chain performance. We welcome further technical questions and can provide documentation or regulatory filings to support your quality assurance and registration processes.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
